Kardiyak İmplante Edilebilir Elektronik Cihaz İmplantasyon Sürecinde Antikoagülan Tedavi ve Antibiyotik Proflaksisi

Adalet K. Klinik kardiyoloji tanı ve tedavi, İstanbul Tıp Kitapevi 2013. 729-774.
Giudici MC, Paul DL, Bontu P, et al. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin Electrophysiology 27: 358, 2004.
Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace 2015;17:767777.
de Oliveira JC, Martinelli M, Nishioka SA, et al.. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:2934.
Essebag V, Verma A, Healey JS, et al. BRUISE CONTROL Investigators. Clinically significant pocket hematoma increases longterm risk of device infection: BRUISE CONTROL INFECTION Study. J Am Coll Cardiol 2016;67:13001308.
Birnie DH, Healey JS, Wells GA, et al. BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368:20842093.
Malagu M, Trevisan F, Scalone A, et al. Frequency of ‘pocket’ hematoma in patients receiving vitamin K antagonist and antiplatelet therapy at the time of pacemaker or cardioverter defibrillator implantation (from the POCKET Study). Am J Cardiol 2017;119:10361040.
Birnie DH, Healey JS, Wells GA, et al. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J 2018;39:39733979
Traykov V, Bongiorni MG, Boriani G, et al. Clinical practice and implementation of guidelines for the prevention, diagnosis and management of cardiac implantable electronic device infections: results of a worldwide survey under the auspices of the European Heart Rhythm Association. Europace 2019;21:12701279
Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol 2010;3:312318.
Tompkins C, Cheng A, Dalal D, et al. Dual antiplatelet therapy and heparin ‘bridging’ significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol 2010;55:23762382.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal (2021) 00, 194. doi:10.1093/eurheartj/ehab364.
2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation Europace (2021) 23, 1612–1676. doi:10.1093/europace/euab065.
Enzler MJ, Berbari E, Osmon DR. Antimicrobial prophylaxis in adults. Mayo Clin Proc 2011;86:686701.
Madadi S, Kafi M, Kheirkhah J, et al. Postoperative antibiotic prophylaxis in the prevention of cardiac implantable electronic device infection. Pacing Clin Electrophysiol 2019;42:161165.
Krahn AD, Longtin Y, Philippon F, et al. Prevention of arrhythmia device infection trial: the PADIT trial. J Am Coll Cardiol 2018;72:30983109
Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction : Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management. Heart Rhythym 6 : 1085, 2009.